

**UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF VIRGINIA  
ALEXANDRIA DIVISION**

JANINE ALI,

Plaintiff,

vs.

ELI LILLY AND COMPANY, an Indiana  
corporation,

Defendant.

1:14-cv-01615-AJT-JFA

**ELI LILLY AND COMPANY’S EXHIBIT LIST**

Pursuant to the Court’s Orders and Federal Rule of Civil Procedure 26, Eli Lilly and Company (“Lilly”) hereby submits the following Exhibit List containing the documents Lilly anticipates offering at trial, except for purposes of impeachment or rebuttal. Lilly also reserves the right to use any document on Plaintiff’s witness list.

<b>Exhibit No.</b>	<b>Description</b>	<b>Beg. Bates</b>
DTX 400	Medical Information Letter: 12-2009 [Designated as Perahia Ex. 23]	CYM-01727822
DTX 401	Letter to Lilly from FDA, 08-03-2004 [Designated as Hoog Ex.18]	CYM-00727991
DTX 402	Clinical Study Report: HMAT(b)	CYM-01054242
DTX 403	Clinical Study Report: HMAQ(b)	CYM-01033964
DTX 404	Clinical Study Report: HMAQ(a)	CYM-01028897
DTX 405	Clinical Study Report: HMBH(b)	CYM-01057305
DTX 406	Clinical Study Report: HMBH(a)	CYM-01026706
DTX 407	Clinical Study Report: HMAY(a)	CYM-00870792
DTX 408	Clinical Study Report: HMAY(b)	CYM-01493802
DTX 409	Labeling Submission (excerpt), 11-09-2009	CYM 00159616
DTX 410	Cymbalta Label: PV7216AMP, 04-15-2011	CYM-00009437

DTX 411	Cymbalta Label: PV7217AMP, 04-22-2011	CYM-00009679
DTX 412	Cymbalta Label: PV7218AMP, 05-06-2011	CYM-00011724
DTX 413	Cymbalta Label: PV7213AMP, 11-15-2010	CYM-00011821
DTX 414	Cymbalta Label: PV7219AMP, 09-07-2011	CYM-00028678
DTX 415	Email to A. Gibson from P. Burns with Jan. 26, 2005 Letter to Lilly from FDA, 01-27-2005	CYM-00728996
DTX 416	Labeling Submission (excerpt), 01-30-2009	CYM-00081925
DTX 417	2009 Annual Report	CYM-00131537
DTX 418	2009 Labeling Summary	CYM-00131542
DTX 419	PSUR 9 Aug 2008 - Aug 2009	CYM-00131805
DTX 420	Labeling Submission (excerpt), 05-13-2009	CYM-00142819
DTX 421	Email to A. Gibson from B. Boggs with Mar. 18, 2009 Letter to Lilly from FDA, 03-20-2009	CYM-00161214
DTX 422	Cymbalta Medication Guide: PV5084AMP, 12-04-2008	CYM-00161246
DTX 423	Email to A. Gibson from B. Boggs with Apr. 16, 2009 Letter to Lilly from FDA, 04-17-2009	CYM-00161257
DTX 424	Clinical Study Report: HMEN - Extension	CYM-00183824
DTX 425	Clinical Study Report: HMEO	CYM-00186881
DTX 426	Clinical Study Report: HMFG	CYM-00191636
DTX 427	Multistudy-analyses Reports of Analyses of Data from More than One Study for Cymbalta (Duloxetine hydrochloride) Chronic Pain, 05-12-09	CYM-00193633
DTX 428	2010 Annual Report	CYM-00288781
DTX 429	2010 Labeling Summary	CYM-00288810
DTX 430	PSUR 10 Aug 2009- Aug 2010	CYM-00289558
DTX 431	Labeling Submission (excerpt), 02-11-2011	CYM-00300195
DTX 432	Letter to Lilly from FDA, 11-19-2009	CYM-00300503
DTX 433	Cymbalta Label: PV7211AMP, 01-13-2010	CYM-00301254
DTX 434	Letter to Lilly from FDA, 12-20-2010	CYM-00301315
DTX 435	Email to Lilly from FDA, 02-11-2011	CYM-00301323
DTX 436	Labeling Submission (excerpt), 05-28-2010	CYM-00301444
DTX 437	Email from M. Kuntz to A. Gibson with Nov. 4, 2010 Letter to Lilly from FDA, 11-04-2010	CYM-00304559
DTX 438	Cymbalta Medication Guide: PV7090AMP, 02-16-2009	CYM-00304596
DTX 439	Cymbalta Label: PV7215AMP, 04-13-2011	CYM-00315316
DTX 440	2011 Annual Report	CYM-00317711
DTX 441	Cymbalta Label: PV7214AMP, 03-04-2011	CYM-00317715
DTX 442	2011 Labeling Summary	CYM-00317769
DTX 443	Labeling Submission (excerpt), 04-14-2011	CYM-00318029
DTX 444	Labeling Submission (excerpt), 08-10-2011	CYM-00324129
DTX 445	Letter to Lilly from FDA, 09-02-2011	CYM-00324408
DTX 446	Email to FDA from Lilly, 08-17-2011	CYM-00324648
DTX 447	PSUR 11 Aug 2010- Aug 2011	CYM-00331576
DTX 448	2012 Annual Report	CYM-00504449
DTX 449	2012 Labeling Summary	CYM-00504452

DTX 450	Labeling Submission (excerpt), 04-30-2012	CYM-00505018
DTX 451	PSUR 12 Aug 2011- Aug 2012	CYM-00512955
DTX 452	Letter to FDA from Lilly, 06-03-1991	CYM-00526490
DTX 453	Clinical Study Report: HMDV	CYM-00570202
DTX 454	Clinical Study Report: HMEN	CYM-00588976
DTX 455	Clinical Study Report: HMEP	CYM-00593220
DTX 456	Cymbalta Label: PV3604AMP, 08-09-2005	CYM-00677032
DTX 457	Labeling Submission (excerpt), 10-11-2005	CYM-00677117
DTX 458	Cymbalta Label: PV3605AMP, 10-11-2005	CYM-00677202
DTX 459	Cymbalta Label: PV3601AMP, 09-03-2004	CYM-00679036
DTX 460	Cymbalta Medication Guide: PV5081AMP, 01-26-2005	CYM-00681579
DTX 461	Integrated Summary of Safety, 10-10-2001	CYM-00701344
DTX 462	Labeling Submission (excerpt), 03-24-2003	CYM-00705947
DTX 463	PADER, NDA 21-427, 12-03-2004	CYM-00713404
DTX 464	PSUR 1 Aug 2004 - Feb 2005	CYM-00715114
DTX 465	PADER, NDA 21-427, 06-01-2005	CYM-00717617
DTX 466	PSUR 2 Feb 2005 - Aug 2005	CYM-00719280
DTX 467	2005 Annual Report	CYM-00722811
DTX 468	2005 Labeling Summary	CYM-00722822
DTX 469	PADER, NDA 21-427, 12-02-2005	CYM-00723502
DTX 470	Labeling Submission (excerpt), 11-12-2001	CYM-00725746
DTX 471	Cymbalta Label: NL 3600 AMP	CYM-00725814
DTX 472	Cymbalta Draft Label, 09-29-2003	CYM-00727880
DTX 473	Cymbalta Draft Label, 07-15-2004	CYM-00727969
DTX 474	Letter to Lilly from FDA, 08-03-2004	CYM-00727991
DTX 475	Letter to Lilly from FDA, 10-15-2004	CYM-00728261
DTX 476	Email to A. Gibson from P. Burns, with Jan. 12, 2005 Letter to Lilly from FDA, 01-12-2005	CYM-00728875
DTX 477	Labeling Submission (excerpt), 01-23-2006	CYM-00733942
DTX 478	Cymbalta Label: PV3606AMP, 01-23-2006	CYM-00735753
DTX 479	Clinical Study Report: HMBR	CYM-00745262
DTX 480	Clinical Study Report: HMDT	CYM-00750820
DTX 481	Clinical Study Report: HMDU	CYM-00755360
DTX 482	Clinical Study Report: HMAV(a)	CYM-00772736
DTX 483	Clinical Study Report: HMAV(b) - Abbreviated	CYM-00776920
DTX 484	Clinical Study Report: HMDD	CYM-00806596
DTX 485	Clinical Study Report: SBBR	CYM-00821165
DTX 486	Clinical Study Report: SBBT	CYM-00823606
DTX 487	Clinical Study Report: SBBU	CYM-00824601
DTX 488	PSUR 3 Aug 2005 - Feb 2006	CYM-00861952
DTX 489	Clinical Study Report: HMBV	CYM-00890049
DTX 490	Clinical Study Report: SBBL	CYM-00898475
DTX 491	Labeling Submission (excerpt), 04-27-2006	CYM-00944957
DTX 492	Letter to Lilly from FDA, 06-06-2006	CYM-00945926
DTX 493	PADER, NDA 21-427, 05-31-2006	CYM-00946003

DTX 494	Cymbalta Label: PV3607AMP, 08-30-2006	CYM-00947616
DTX 495	PSUR 4 Feb 2006 - Aug 2006	CYM-00947704
DTX 496	Cymbalta Label: PV3608AMP, 09-15-2006	CYM-00954492
DTX 497	Clinical Study Report: HMBT	CYM-00955529
DTX 498	Cymbalta Label: PV3609AMP, 10-04-2006	CYM-00959730
DTX 499	PADER, NDA 21-427, 11-30-2006	CYM-00960485
DTX 500	PADER, NDA 21-427, 05-31-2007	CYM-00962156
DTX 501	PSUR 5 Aug 2006- 2007	CYM-00963610
DTX 502	Cymbalta Label: PV3600AMP, 08-03-2004	CYM-00967892
DTX 503	Cymbalta Label: PV3602AMP, 01-12-2005	CYM-00971560
DTX 504	Cymbalta Label: PV3603AMP, 01-26-2005	CYM-00973434
DTX 505	2007 Annual Report	CYM-00977185
DTX 506	2007 Labeling Summary	CYM-00977207
DTX 507	Labeling Submission (excerpt), 10-31-2006	CYM-00978617; CYM-00978764
DTX 508	2006 Annual Report	CYM-01008240
DTX 509	2006 Labeling Summary	CYM-01008251
DTX 510	Clinical Study Report: HMAT(a)	CYM-01030818
DTX 511	Cymbalta Label: PV5900AMP, 02-23-2007	CYM-01081105
DTX 512	Cymbalta Label: PV5901AMP, 03-01-2007	CYM-01081516
DTX 513	Email to FDA from Lilly, 06-22-2007	CYM-01082644
DTX 514	Cymbalta Label: PV5903AMP, 05-31-2007	CYM-01085425
DTX 515	Cymbalta Medication Guide: PV5082AMP, 05-01-2007	CYM-01085453
DTX 516	Cymbalta Label: PV5904AMP, 06-28-2007	CYM-01088714
DTX 517	Cymbalta Label: PV5907AMP, 12-13-2007	CYM-01092811
DTX 518	Letter to FDA from Lilly, 12-13-2007	CYM-01093768
DTX 519	Cymbalta Label: PV5905AMP, 10-25-2007	CYM-01095276
DTX 520	Cymbalta Label: PV5906AMP, 11-28-2007	CYM-01097939
DTX 521	PSUR 7 Aug 2007 - Feb 2008	CYM-01099044
DTX 522	PSUR 6 Feb 2007 - Aug 2007	CYM-01103692
DTX 523	2008 Annual Report	CYM-01107432
DTX 524	Labeling Submission (excerpt), 05-17-2007	CYM-01111111; CYM-01111108
DTX 525	Cymbalta Label: PV5902AMP, 05-17-2007	CYM-01111148
DTX 526	Letter to Lilly from FDA, 05-01-2007	CYM-01111684
DTX 527	Labeling Submission (excerpt), 10-25-2007	CYM-01113163; CYM-01113160
DTX 528	Email to Lilly, M. Lunik from B. Boggs with Nov. 28, 2007 Letter to Lilly from FDA, 11-29-2007	CYM-01113345
DTX 529	Email to S. Ottinger from B. Boggs, 06-10-2008	CYM-01117594
DTX 530	Labeling Submission (excerpt), 08-11-2008	CYM-01117607
DTX 531	PSUR 8 Feb 2008 - Aug 2008	CYM-01117943
DTX 532	Cymbalta Label: PV5909AMP, 08-11-2008	CYM-01124388
DTX 533	Cymbalta Label: PV6860AMP, 12-04-2008	CYM-01124399

DTX 534	Cymbalta Label: PV6860AMP, 12-04-2008 [Designated as Glenmullen Ex. 04]	CYM-01124399
DTX 535	Cymbalta Label: PV6860AMP, 12-04-2008 [Designated as Morris Ex. 04]	CYM-01124399
DTX 536	Cymbalta Label: PV5908AMP, 06-13-2008	CYM-01125423
DTX 537	Cymbalta Label: PV6862AMP, 02-16-2009	CYM-01136268
DTX 538	Letter to FDA from Lilly, 08-14-2007	CYM-01137080
DTX 539	Clinical Study Report: HMCA	CYM-01142733
DTX 540	Letter to Lilly from FDA, 06-13-2008	CYM-01183976
DTX 541	Cymbalta Medication Guide: PV5083AMP, 06-21-2007	CYM-01184009
DTX 542	Clinical Study Report: HMEH	CYM-01191333
DTX 543	Additional Analyses for Safety for Duloxetine Hydrochloride Fibromyalgia (excerpt), 08-08-07	CYM-01199292
DTX 544	Letter to Lilly from FDA, 09-03-2004	CYM-01206982
DTX 545	Labeling Submission (excerpt), 03-02-2004	CYM-01207255; CYM-01207155
DTX 546	Clinical Study Report: HMBC	CYM-01213266
DTX 547	Clinical Study Report: HMBT 6-month exposure	CYM-01215476
DTX 548	Clinical Study Report: HMAV(a) - Acute	CYM-01220120
DTX 549	Labeling Submission (excerpt), 12-04-2008	CYM-01545782
DTX 550	Letter to Lilly from FDA, 02-23-2007	CYM-01548235
DTX 551	Cymbalta Label: PV6863AMP, 11-19-2009	CYM-01703746
DTX 552	Cymbalta Label: PV7212AMP, 11-04-2010	CYM-01720936
DTX 553	Medical Information Letter: 04-2010	CYM-01727818
DTX 554	Medical Information Letter: 12-2009	CYM-01727822
DTX 555	Medical Information Letter: 02-2013	CYM-01727826
DTX 556	Medical Information Letter: 02-2005	CYM-01727834
DTX 557	Medical Information Letter: 02-2009	CYM-01727839
DTX 558	Medical Information Letter: 02-2009	CYM-01727839
DTX 559	Medical Information Letter: 01-2007	CYM-01727843
DTX 560	Medical Information Letter: 01-2012	CYM-01727852
DTX 561	Medical Information Letter: 11-2010	CYM-01727856
DTX 562	Medical Information Letter: 10-2004	CYM-01727860
DTX 563	Medical Information Letter: 09-2006	CYM-01727865
DTX 564	Medical Information Letter: 09-2007	CYM-01727876
DTX 565	Email from FDA to Lilly, 10-21-2004	CYM-01735330
DTX 566	Cymbalta Medication Guide: PV5080AMP, 01-12-2005	CYM-01737170
DTX 567	2008 Labeling Summary	CYM-01737202
DTX 568	Cymbalta Draft Label: 0.35 NL 3600 AMP, 06-17-2004	CYM-01793264
DTX 569	CDER, Cross Discipline Team Leader Review, NDA 22-148, Approval Date 06-13-2008	n/a
DTX 570	Letter to Lilly from FDA, 02-18-2005	n/a
DTX 571	Letter to Lilly from FDA, 08-02-2007	n/a

DTX 572	Arnold, Lesley M. et al., A Double-Blind, Multicenter Trial Comparing Duloxetine With Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder, Arthritis & Rheumatism (2004)	n/a
DTX 573	Arnold, Lesley M. et al., A randomized, double-blind, placebo controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder, Pain (2005)	n/a
DTX 574	Arnold, Lesley M., Review Biology and therapy of fibromyalgia: New therapies in fibromyalgia, Arthritis Research & Therapy (2006)	n/a
DTX 575	Arnold, Lesley M. et al., Comparisons of the Efficacy and Safety of Duloxetine for the Treatment of Fibromyalgia in Patients with Versus Without Major Depressive Order, Clinical Journal of Pain (2009)	n/a
DTX 576	Arnold, Lesley M. et al., Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: A Randomized, double-blind, Placebo-controlled Trial, Journal of Rheumatology (2010)	n/a
DTX 577	Arnold, Lesley M. et al., Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial, Arthritis Research & Therapy (2011)	n/a
DTX 578	Berger, A. et al., Characteristics and healthcare costs of patients with fibromyalgia syndrome, International Journal of Clinical Practice (2007)	n/a
DTX 579	Cascade, Elisa et al., Real-World Data on SSRI Antidepressant Side Effects, Psychiatry (Edgemont) (2009)	n/a
DTX 580	Clauw, Daniel J., Fibromyalgia: A clinical review, Journal of the American Medical Association (2014)	n/a
DTX 581	Cruz, Martin P. et al., Duloxetine HCl (Cymbalta) for the Treatment of Depression, Neuropathic Pain, Fibromyalgia, and Stress Urinary Incontinence, P&T (2006)	n/a
DTX 582	Dussias, Peter et al., Treatment of Fibromyalgia, Psychiatry (Edgemont) (2010)	n/a
DTX 583	Julien, Nancy et al., Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition, Pain (2005)	n/a
DTX 584	Holliday, Kate L. et al., Recent Advances in the Understanding of Genetic Susceptibility to Chronic Pain and Somatic Symptoms, Current Rheumatology Reports (2011)	n/a
DTX 585	Hsu, Eric S., Acute and Chronic Pain Management in Fibromyalgia: Updates on Pharmacotherapy, American Journal of Therapeutics (2011)	n/a
DTX 586	Kato, K. et al., A population-based twin study of functional somatic syndromes, Psychological Medicine (2009)	n/a

DTX 587	Kleinman, Nathan et al., Burden of Fibromyalgia and Comparisons With Osteoarthritis in the Workforce, Journal of Occupational and Environmental Medicine (2009)	n/a
DTX 588	Lyrica Label: 08-2011	n/a
DTX 589	McBeth, John et al., Epidemiology of chronic musculoskeletal pain, Best Practice & Research Clinical Rheumatology (2007)	n/a
DTX 590	McCarberg, Bill H., Clinical Overview of Fibromyalgia, American Journal of Therapeutics (2012)	n/a
DTX 591	Mease, Philip J. et al., Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia, Semin Arthritis Rheum (2010)	n/a
DTX 592	Pergolizzi, Joseph V. et al., A Review of Duloxetine 60 mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain, Pain Practice (2012)	n/a
DTX 593	Phillips, Kristine et al., Central Pain Mechanisms in the Rheumatic Diseases, Arthritis & Rheumatism (2013)	n/a
DTX 594	Duloxetine in fibromyalgia, Prescrire International (2009)	n/a
DTX 595	Rahman, Anisur et al., Fibromyalgia, Clinical review, BMJ (2014)	n/a
DTX 596	Russell, Jon et al., Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with out without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial, Pain (2008)	n/a
DTX 597	Sansone, Randy A. et al., Serotonin Norepinephrine Reuptake Inhibitors: A Pharmacological Comparison, Innovations In Clinical Neuroscience (2014)	n/a
DTX 598	Staud, Roland et al., Mechanisms of Disease: pain in fibromyalgia syndrome, Nature Reviews Rheumatology (2006)	n/a
DTX 599	Üçeyler, Nurcan et al., Anticonvulsants for fibromyalgia, The Cochrane Collaboration (2013)	n/a
DTX 600	White, Leigh Ann et al., Employees With Fibromyalgia: Medical Comorbidity, Healthcare Costs, and Work Loss, Journal of Occupational and Environmental Medicine (2008)	n/a
DTX 601	Wolfe, Frederick et al., The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee, Arthritis Rheum (1990)	n/a
DTX 602	Wolfe, Frederick et al., The prevalence and characteristics of fibromyalgia in the general population, Arthritis Rheum (1995)	n/a

DTX 603	Wolfe, Frederick et al., Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia, Journal of Rheumatology (2011)	n/a
DTX 604	Wright, Alan et al., Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy, Journal of Pain Research (2010)	n/a
DTX 605	World Health Organization, Global Health Estimates 2014 Summary Tables: DALY BY CAUSE, AGE AND SEX, BY WORLD BANK INCOME CATEGORY, 2000-2012 (2012), <a href="http://www.who.int/healthinfo/global_burden_disease/en/">http://www.who.int/healthinfo/global_burden_disease/en/</a>	n/a
DTX 606	Allgulander, C. et al., A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder, Journal of Psychopharmacology (2008)	n/a
DTX 607	Anxiety and Depression Association of America, Facts & Statistics (2014), <a href="http://www.adaa.org/about-adaa/press-room/facts-statistics">http://www.adaa.org/about-adaa/press-room/facts-statistics</a>	n/a
DTX 608	Blier, Pierre et al., Physiologic mechanisms underlying the antidepressant discontinuation syndrome, Journal of Clinical Psychiatry (2006)	n/a
DTX 609	Bystritsky, Alexander, Pharmacotherapy for generalized anxiety disorder, UpToDate (2014), <a href="http://www.uptodate.com/contents/pharmacotherapy-for-generalized-anxiety-disorder">http://www.uptodate.com/contents/pharmacotherapy-for-generalized-anxiety-disorder</a>	n/a
DTX 610	Depression and Bipolar Support Alliance (DBSA), Depression Statistics, DBSA (2014), <a href="http://www.dbsalliance.org/site/PageServer?pagename=education_statistics_depression">http://www.dbsalliance.org/site/PageServer?pagename=education_statistics_depression</a>	n/a
DTX 611	CDER, Medical Review #2, NDA 21-427, Approval Date 08-03-2004	n/a
DTX 612	Hall-Flavin, Daniel K., Antidepressant Withdrawal: Is There Such a Thing?, Mayo Clinic, (2013) <a href="http://www.mayoclinic.org/diseases-conditions/depression/expert-answers/antidepressant-withdrawal/faq-20058133">http://www.mayoclinic.org/diseases-conditions/depression/expert-answers/antidepressant-withdrawal/faq-20058133</a>	n/a
DTX 613	Jarrett Robin B. et al., Unipolar depression in adults: Continuation and maintenance treatment, UpToDate (2014), <a href="http://www.uptodate.com/contents/unipolar-depression-in-adults-continuation-and-maintenance-treatment">http://www.uptodate.com/contents/unipolar-depression-in-adults-continuation-and-maintenance-treatment</a>	n/a
DTX 614	Lyness, Jeffrey M., Unipolar depression in adults: Assessment and diagnosis, UpToDate (2014) <a href="http://www.uptodate.com/contents/unipolar-depression-in-adults-assessment-and-diagnosis">http://www.uptodate.com/contents/unipolar-depression-in-adults-assessment-and-diagnosis</a>	n/a



DTX 615	Centers for Disease Control and Prevention, Current Depression Among Adults - United States, 2006 and 2008, MMWR Morbidity and Mortality Weekly Report (2010)	n/a
DTX 616	National Institute of Mental Health, Depression, National Institutes of Health (Publication No. 11-3561) (2011), <a href="http://infocenter.nimh.nih.gov/nimh/product/Depression/NIH%2011-3561">http://infocenter.nimh.nih.gov/nimh/product/Depression/NIH %2011-3561</a>	n/a
DTX 617	Perahia, David G. et al., Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder, Journal of Affective Disorders (2005),	n/a
DTX 618	Pinkerton, JoAnn V. et al., Menstrual cycle-related exacerbation of disease, American Journal of Obstetrics & Gynecology (2010)	n/a
DTX 619	Rosenbaum, Jerrold F. et al., Clinical Management of Antidepressant Discontinuation, J. Clin. Psychiatry (1997)	n/a
DTX 620	Schatzberg, Alan F. et al., Antidepressant Discontinuation Syndrome: Consensus Panel Recommendations for Clinical Management and Additional Research, J. Clin. Psychiatry (2006)	n/a
DTX 621	Warner, Christopher H. et al., Antidepressant Discontinuation Syndrome, American Family Physician (2006)	n/a
DTX 622	WebMD, Antidepressant Withdrawal (2014) <a href="http://www.webmd.com/depression/guide/withdrawal-from-antidepressants">http://www.webmd.com/depression/guide/withdrawal-from-antidepressants</a> ,	n/a
DTX 623	World Health Organization Depression Fact Sheet No. 369, October 2012, World Health Organization (2012) <a href="http://www.who.int/mediacentre/factsheets/fs369/en/">http://www.who.int/mediacentre/factsheets/fs369/en/</a>	n/a
DTX 624	Zajecka, John et al., Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review, J. Clin. Psychiatry (1997)	n/a
DTX 625	FDA, Guidance for Industry: Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products — Content and Format (2006)	n/a
DTX 626	FDA, Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (2005)	n/a
DTX 627	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline: Pharmacovigilance Planning E2E (2004)	n/a
DTX 628	FDA, Guidance for Industry: Providing Postmarket Periodic Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report) (2013)	n/a
DTX 629	Haddad, Peter M., Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management, Drug Safety (2001)	n/a

DTX 630	UCLA, Antidepressants, The Handbook of Psychiatry (Guze, Barry et al. eds, 1990)	n/a
DTX 631	American Psychiatric Association, Practice Guideline for Major Depressive Disorder in Adults, American Journal of Psychiatry (1993)	n/a
DTX 632	American Psychiatric Association, Practice Guideline for the Treatment of Patients with Major Depressive Disorder, American Journal of Psychiatry (2d ed. 2000), <a href="http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd">http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd</a>	n/a
DTX 633	UCLA, The Psychiatric Drug Handbook (Guze, Barry et al. eds, 1992)	n/a
DTX 634	FDA Anesthetic Life Support Drugs Advisory Committee Meeting, Food and Drug Administration (Aug. 19, 2010)	n/a
DTX 635	Letter to Wyeth Pharmaceuticals Inc. from FDA, 12-12-2012	n/a
DTX 636	Celexa Label: 11-19-2002	n/a
DTX 637	Effexor Label: 01-31-2003	n/a
DTX 638	Lexapro Approval Package, 21-323/S-003 & 21-365/S-004	n/a
DTX 639	Paxil Review Package, NDA 20-031/S-029	n/a
DTX 640	Zoloft Label: 08-19-2004	n/a
DTX 641	Lexapro Label: 08-02-2007	n/a
DTX 642	Celexa Label: 07-17-1998	n/a
DTX 643	Paxil Label: 05-11-1999	n/a
DTX 644	FDA, Adverse Event Reporting System (FAERS) (2014)	n/a
DTX 645	CDER, Pharmacology Review #2, NDA 21-427, Approval Date 08-03-2004	n/a
DTX 646	Celexa Label: 07-08-2014	n/a
DTX 647	Effexor Label: 12-12-2012	n/a
DTX 648	Lexapro Label: 07-08-2014	n/a
DTX 649	Paxil Label: 07-18-2014	n/a
DTX 650	Zoloft Label: 09-12-2014	n/a
DTX 651	Cymbalta Labeling Changes Chronology	n/a
DTX 652	Cymbalta Medication Guide Changes Timeline	n/a
DTX 653	American Psychiatric Publishing (APP), The American Psychiatric Publishing Textbook of Psychiatry (Hales, Robert E. et al. eds. 5th ed. 2008)	n/a
DTX 654	American Psychiatric Publishing (APP), The American Psychiatric Publishing Textbook of Psychiatry (Hales, Robert E. et al. eds. 6th ed. 2014)	n/a
DTX 655	American Psychiatric Association, Practice Guideline for the Treatment of Patients with Major Depressive Disorder (3d ed. 2010)	n/a
DTX 656	Lyrica Label: 12-2013	n/a
DTX 657	Letter to GlaxoSmithKline from FDA, 01-12-2005	n/a

DTX 658	CDER, Medical Review #3, NDA 21-427, Approval Date 08-03-2004	n/a
DTX 659	CDER, Pharmacology Review #3, NDA 21-427, Approval Date 08-03-2004	n/a
DTX 660	Fava, Maurizio et al., Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine, Am. J. Psychiatry (1997)	n/a
DTX 661	Fava, M., Prospective Studies of Adverse Events Related to Antidepressant Discontinuation, J. Clin. Psychiatry (2006)	n/a
DTX 662	Giakas, WJ et al., Intractable Withdrawal from Venlafaxine Treated with Fluoxetine, Psychiatric Annals (1997)	n/a
DTX 663	Haddad, Peter M., Newer Antidepressants and the Discontinuation Syndrome, J. Clin. Psychiatry (1997)	n/a
DTX 664	Kaplan, Eric, Antidepressant Noncompliance as a Factor in the Discontinuation Syndrome, J. Clin. Psychiatry (1997)	n/a
DTX 665	Lejoyeux, Michel, et al., Antidepressant Discontinuation: A Review of the Literature, J. Clin. Psychiatry (1997)	n/a
DTX 666	Schatzberg, Alan F. et al., Serotonin Reuptake Inhibitor Discontinuation Syndrome: Hypothetical Definition, J. Clin. Psychiatry (1997)	n/a
DTX 667	Schatzberg, Alan F. et al., Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome, J. Clin. Psychiatry (1997)	n/a
DTX 668	Schatzberg, Alan F. et al., Antidepressant Discontinuation Syndrome: An Update on Serotonin Reuptake Inhibitors, J. Clin. Psychiatry 1997)	n/a
DTX 669	Young, A.H. et al., Physicians' Knowledge of Antidepressant Withdrawal Effects: A Survey, J. Clin. Psychiatry (1997)	n/a
DTX 670	Perahia, David G.S. et al., A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder, Journal of Psychiatric Research (2008) [Designated as Perahia Ex. 22]	n/a
DTX 671	Cymbalta Labeling Changes Chronology [Designated as Becker Ex. 05]	n/a
DTX 672	Cymbalta Medication Guide Changes Timeline [Designated as Becker Ex. 06]	n/a
DTX 673	Perahia, David G. et al., Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder, Journal of Affective Disorders (2005) [Designated as Glenmullen Ex. 03]	n/a
DTX 674	Paxil Label: 07-18-2014 [Designated as Glenmullen Ex. 06]	n/a
DTX 675	Perahia, David G. et al., Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder, Journal of Affective Disorders (2005) [Designated as Morris 06]	n/a
DTX 676	Paxil Label: 07-18-2014 [Designated as Morris Ex. 10]	n/a

DTX 677	Cymbalta Label: A NL3606AMP [Designated as Herrera Ex. 02]	n/a
DTX 678	Letter to FDA from Lilly (excerpt), 05-15-2009	CYM-00181988
DTX 679	Sales Aid, 2007	CYM-01083233
DTX 680	Sales Aid, 2007	CYM-01083299
DTX 681	Sales Aid, 2007	CYM-01085318
DTX 682	Sales Aid, 2007	CYM-01089658
DTX 683	FDA Submission (excerpt), 05-15-2008	CYM-00581799
DTX 684	FDA Submission (excerpt), 03-24-2003	CYM-00705893
DTX 685	FDA Submission (excerpt), 04-13-2007	CYM-01083232
DTX 686	FDA Submission (excerpt), 05-31-2007	CYM-01085286
DTX 687	Sales Aid, 2008	CYM-01098048
DTX 688	Sales Aid, 2008	CYM-01098248
DTX 689	Sales Aid, 2008	CYM-01124018
DTX 690	Sales Aid, 2008	CYM-01132411
DTX 691	Sales Aid, 2009	CYM-01135815
DTX 692	Sales Aid, 2009	CYM-01135884
DTX 693	FDA Submission (excerpt), 11-30-1999	CYM-01606967
DTX 694	Letter to Lilly from FDA, 01-14-2000	CYM-01607049
DTX 695	Implementation Guide, 2004	CYM-01866309
DTX 696	Letter from Lilly to FDA (excerpt), 05-15-2009	CYM-00181988
DTX 697	Complaint, Ali (Ed Va.) (ECF 01), 11-26-2014	n/a
DTX 698	Buchwald, A., A review of the evidence for overlap among unexplained clinical conditions, Annals of Internal Medicine (2001)	n/a
DTX 699	Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Current Medical Research and Opinion (2007)	n/a
DTX 700	Hales RE, Yudofsky SC, and Gabbard (GO). American Psychiatric Publishing Textbook of Psychiatry 2008; (5th ed.) Washington, DC: American Psychiatric Association.	n/a
DTX 701	Clinical Study Report: 102G	CYM-00704465
DTX 702	Clinical Study Report: 221G	CYM-00704522
DTX 703	NDA 21-427, 11-12-2001	CYM-00704575
DTX 704	Clinical Study Report: 311G	CYM-00704639
DTX 705	Clinical Study Report: 312G	CYM-00704723
DTX 706	Clinical Study Report: 313G	CYM-00704934
DTX 707	Clinical Study Report: 322G	CYM-00705033
DTX 708	Clinical Study Report: 323G	CYM-00705125
DTX 709	Clinical Study Report: 324G	CYM-00705218
DTX 710	Clinical Study Report: 401G	CYM-00705312
DTX 711	NDA 21-427, 11-12-2001	CYM-00705365
DTX 712	Clinical Study Report: 1009	CYM-00705561

DTX 713	NDA 21-427, 11-12-2001	CYM-00700162
DTX 714	Letter to FDA from Lilly, 03-24-2003	CYM-00705896
DTX 715	Clinical Study Report: E001	CYM-01488751
DTX 716	Clinical Study Report: HMAG	CYM-00700335
DTX 717	Clinical Study Report: HMAH	CYM-00700642
DTX 718	Clinical Study Report: HMAI	CYM-01023292
DTX 719	Clinical Study Report: HMAW	CYM-00703214
DTX 720	Clinical Study Report: HMAY(b) - Treatment of Depression (b)	CYM-00700257
DTX 721	Clinical Study Report: HMAY(b) - Treatment of Depression (a)	CYM-00700199
DTX 722	Clinical Study Report: SAAA	CYM-01488829
DTX 723	Clinical Study Report: SAAB - Abbreviated	CYM-01489058
DTX 724	Clinical Study Report: SAAH - Synopsis	CYM-00703280
DTX 725	Clinical Study Report: SAAI - Synopsis	CYM-00703421
DTX 726	Clinical Study Report: SAAL - Abbreviated	CYM-01489337
DTX 727	Clinical Study Report: SAAW	CYM-01489689
DTX 728	Clinical Study Report: SBAM - Abbreviated	CYM-00703743
DTX 729	Clinical Study Report: SBAT - Abbreviated	CYM-00703860
DTX 730	Clinical Study Report: SBAU - Abbreviated	CYM-00703981
DTX 731	Clinical Study Report: SBAV	CYM-00704033
DTX 732	Clinical Study Report: SBAW - Clinical Table of Contents	CYM-00704177
DTX 733	Clinical Study Report: SBAX - Abbreviated	CYM-00704235
DTX 734	Clinical Study Report: SBAY - Abbreviated	CYM-00704330
DTX 735	Clinical Study Report: SBBL - Abbreviated	CYM-00704381
DTX 736	Clinical Study Report: 321G Synopsis	CYM-01217798
DTX 737	Clinical Study Report: Background Overview	CYM-01217869
DTX 738	Clinical Study Report: HMAV(a) - Extension Synopsis	CYM-01221703
DTX 739	Clinical Study Report: HMAV(b) - Synopsis	CYM-81221835
DTX 740	Clinical Study Report: HMAW - Extension	CYM-01221307
DTX 741	Clinical Study Report: HMAW	CYM-01212296
DTX 742	Clinical Study Report: HMBO	CYM-01221956
DTX 743	Clinical Study Report: HMBT - Abbreviated	CYM- 01223629
DTX 744	Clinical Study Report: HMBT	CYM-01215476
DTX 745	Clinical Study Report: HMBU - Synopsis	CYM-01224662
DTX 746	Clinical Study Report: HMBV Synopsis	CYM-01224775
DTX 747	Clinical Study Report: HMBY (Acute) Synopsis	CYM-01224862
DTX 748	Clinical Study Report: HMBY (Extension) Synopsis	CYM-01224923
DTX 749	Clinical Study Report: HMBZ Synopsis	CYM-01217055
DTX 750	Clinical Study Report: HMCA Abbreviated	CYM-01213127
DTX 751	Clinical Study Report: HMCB Abbreviated	CYM-01213194
DTX 752	Clinical Study Report: HMCB	CYM-01213265
DTX 753	Clinical Study Report: HMCN Synopsis	CYM-01217006
DTX 754	Clinical Study Report: HMCQ Synopsis	CYM-01224649
DTX 755	Clinical Study Report: List of Clinical Studies Module 5.2	CYM-01217810

DTX 756	Clinical Study Report: MDD Low Dose	CYM-01226217
DTX 757	Clinical Study Report: SBAB - Abbreviated	CYM-01216281
DTX 758	Clinical Study Report: SBAB - Abbreviated	CYM-01217110
DTX 759	Clinical Study Report: SBAF - Abbreviated	CYM-01225656
DTX 760	Clinical Study Report: SBAF - Abbreviated	CYM-01217229
DTX 761	Clinical Study Report: SBAM - Abbreviated	CYM-01224978
DTX 762	Clinical Study Report: SBAM - Abbreviated	CYM-01217317
DTX 763	Clinical Study Report: SBAU - Synopsis	CYM-01217559
DTX 764	Clinical Study Report: SBAW Synopsis	CYM-01217635
DTX 765	Clinical Study Report: SBAY - Synopsis	CYM-01217696
DTX 766	Clinical Study Report: SBBA - Abbreviated	CYM-01216885
DTX 767	Clinical Study Report: SBBL - Abbreviated	CYM-01225559
DTX 768	Clinical Study Report: SBBM - Abbreviated	CYM-01217745
DTX 769	Clinical Study Report: SBBO - Abbreviated	CYM-01216639
DTX 770	Clinical Study Report: SBBR	CYM-01216784
DTX 771	Clinical Study Report: SBBT	CYM-01216931
DTX 772	Clinical Study Report: SBBX - Abbreviated	CYM-01217483
DTX 773	Clinical Study Report: SBCC - Abbreviated	CYM-01225458
DTX 774	Clinical Study Report: TOC	CYM-01212296
DTX 775	Clinical Study Report: 1008	CYM-00799457
DTX 776	Clinical Study Report: 1009	CYM-00800454
DTX 777	Clinical Study Report: 102G	CYM-00790327
DTX 778	Clinical Study Report: 221G	CYM-00795644
DTX 779	Clinical Study Report: 301G	CYM-00796871
DTX 780	Clinical Study Report: 311G	CYM-01499923
DTX 781	Clinical Study Report: 312G	CYM-01499950
DTX 782	Clinical Study Report: 313G	CYM-00787036
DTX 783	Clinical Study Report: 321G	CYM-00788609
DTX 784	Clinical Study Report: 322G	CYM-00792710
DTX 785	Clinical Study Report: 323G	CYM-00793887
DTX 786	Clinical Study Report: 324G	CYM-00797623
DTX 787	Clinical Study Report: 401G	CYM-00798704
DTX 788	Clinical Study Report: 5.2.1 Tabular Listing of All Clinical Studies	CYM-00818392
DTX 789	Clinical Study Report: HMAV(b) - Extension Abbreviated	CYM-00778429
DTX 790	Clinical Study Report: HMAV(a) - Abbreviated	CYM-00753122
DTX 791	Clinical Study Report: HMAW	CYM-00779233
DTX 792	Clinical Study Report: HMAW - Abbreviated	CYM-00825530
DTX 793	Clinical Study Report: HMAY(b)	CYM-00954150
DTX 794	Clinical Study Report: HMBC	CYM-00880440
DTX 795	Clinical Study Report: HMBO	CYM-00952450
DTX 796	Clinical Study Report: HMBT - Abbreviated	CYM-00951650
DTX 797	Clinical Study Report: HMBU - Synopsis	CYM-00804153
DTX 798	Clinical Study Report: HMBY - Abbreviated	CYM-00804360
DTX 799	Clinical Study Report: HMBY - Abbreviated	CYM-00804465

DTX 800	Clinical Study Report: HMBZ - Abbreviated	CYM-00804563
DTX 801	Clinical Study Report: HMBZ - Abbreviated	CYM-00804677
DTX 802	Clinical Study Report: HMCA	CYM-00784016
DTX 803	Clinical Study Report: HMCB - Abbreviated	CYM-00804815
DTX 804	Clinical Study Report: HMCJ	CYM-00790015
DTX 805	Clinical Study Report: HMCN	CYM-00804941
DTX 806	Clinical Study Report: HMCN	CYM-00805726
DTX 807	Clinical Study Report: HMCQ	CYM-00805921
DTX 808	Clinical Study Report: HMCR	CYM-00806192
DTX 809	Clinical Study Report: HMCR - Extension	CYM-00806365
DTX 810	Clinical Study Report: HMCV	CYM-00862118
DTX 811	Clinical Study Report: HMCZ	CYM-00806581
DTX 812	Clinical Study Report: HMDG	CYM-00806961
DTX 813	Clinical Study Report: HMDH - Synopsis	CYM-00807072
DTX 814	Clinical Study Report: HMDI Synopsis	CYM-00807149
DTX 815	Clinical Study Report: HMDR	CYM-00807240
DTX 816	Clinical Study Report: HMDV	CYM-00738285
DTX 817	Clinical Study Report: HMDW	CYM-00738432
DTX 818	Clinical Study Report: HMEF	CYM-00790139
DTX 819	Clinical Study Report: HMEH	CYM-00790247
DTX 820	Clinical Study Report: HQAC - Abbreviated	CYM-00807372
DTX 821	Clinical Study Report: SBAB	CYM-00807730
DTX 822	Clinical Study Report: SBAB - Synopsis	CYM-00810989
DTX 823	Clinical Study Report: SBAF	CYM-00811160
DTX 824	Clinical Study Report: SBAF - Synopsis	CYM-00816390
DTX 825	Clinical Study Report: SBAM - Abbreviated	CYM-00816684
DTX 826	Clinical Study Report: SBAM - Synopsis	CYM-00818518
DTX 827	Clinical Study Report: SBAT	CYM-00866320
DTX 828	Clinical Study Report: SBAU - Synopsis	CYM-00818787
DTX 829	Clinical Study Report: SBAV	CYM-00892298
DTX 830	Clinical Study Report: SBAW - Synopsis	CYM-00819099
DTX 831	Clinical Study Report: SBAX	CYM-00876205
DTX 832	Clinical Study Report: SBAY - Synopsis	CYM-00819537
DTX 833	Clinical Study Report: SBBA - Abbreviated	CYM-00820201
DTX 834	Clinical Study Report: SBBM - Synopsis	CYM-00820246
DTX 835	Clinical Study Report: SBBO	CYM-00901537
DTX 836	Clinical Study Report: SBBO - Synopsis	CYM-00820563
DTX 837	Clinical Study Report: SBBR - Synopsis	CYM-00823234
DTX 838	Clinical Study Report: SBBX - Abbreviated	CYM-00808804
DTX 839	Clinical Study Report: SBCC - Abbreviated	CYM-00904099
DTX 840	Clinical Study Report: SBCC - Synopsis	CYM-00809099
DTX 841	Clinical Study Report: SBCE - Abbreviated	CYM-00908766
DTX 842	Clinical Study Report: SBCE - Synopsis	CYM-00810786
DTX 843	Clinical Study Report: SBCT - Synopsis	CYM-00810887
DTX 844	Clinical Study Report: Table of Contents	CYM-00818373

DTX 845	ClinStat: Table of Contents	CYM-00982125
DTX 846	Clinical Study Report: HMBC	CYM-00984377
DTX 847	Clinical Study Report: HMDG - Synopsis	CYM-00991735
DTX 848	Clinical Study Report: 5.2.1 Tabular Listing of All Clinical Studies	CYM-01140228
DTX 849	Clinical Study Report: 5.3.5.3. Additional Analyses of Safety for Duloxetine Hydrochloride	CYM-01199292
DTX 850	Clinical Study Report: HMBO	CYM-01189297
DTX 851	Clinical Study Report: HMCJ	CYM-01143897
DTX 852	Clinical Study Report: HMEF	CYM-01151177
DTX 853	NDA 21-427, Note to Reviewer	CYM-00081941
DTX 854	Letter to Lilly from FDA, 08-28-2007	CYM-00570200
DTX 855	Letter to Lilly from FDA, 09-05-2007	CYM-01112692
DTX 856	Clinical Study Report: HMEN - Synopsis	CYM-00183815
DTX 857	Clinical Study Report: HMEO - Synopsis	CYM-00186875
DTX 858	Clinical Study Report: HMEP	CYM-00189878
DTX 859	Clinical Study Report: HMFG - Synopsis	CYM-00191632
DTX 860	Clinical Study Report: 5.2.Tabular Listing of All Clinical Studies	CYM-00183807
DTX 861	Clinical Study Report: 5.3.5.3. Multistudy-Analyses	CYM-00193633
DTX 862	Clinical Study Report: 2.7.6 Synopses of Individual Studies	CYM-00183772
DTX 863	Letter to Lilly from FDA, 03-23-2003	CYM-00705896
DTX 864	Clinical Study Report: HMAY(a)	CYM-01491447
DTX 865	Clinical Study Report: HMAU	CYM-01036949
DTX 866	Letter to FDA from Lilly, 03-12-2002	CYM-00727610
DTX 867	Clinical Study Report: HMAU	CYM-00831146
DTX 868	Clinical Study Report: HMCK	CYM-00342797
DTX 869	Clinical Study Report: HMCK - Synopsis	CYM-00342788
DTX 870	Clinical Study Report: HMCL	CYM-00355944
DTX 871	Clinical Study Report: HMCL - Synopsis	CYM-00355935
DTX 872	Clinical Study Report: HMEQ - Amended Study	CYM-00075461
DTX 873	Clinical Study Report: HMEQ - Synopsis	CYM-00075457
DTX 874	Clinical Study Report: HMFR - Abbreviated	CYM-00312431
DTX 875	Clinical Study Report: HMFR - Synopsis	CYM-00312427
DTX 876	Clinical Study Report: HMGC	CYM-00161639
DTX 877	Clinical Study Report: HMGC - Synopsis	CYM-00161633
DTX 878	Clinical Study Report: HMGL - Synopsis	CYM-00329686
DTX 879	Jann, Michael W. et al., Antidepressant Agents for the Treatment of Chronic Pain and Depression, Pharmacotherapy (2007)	n/a
DTX 880	Mayo Clinic, Diseases and Conditions: Depression (major depressive disorder) (2013), <a href="http://www.mayoclinic.org/diseases-conditions/depression/basics/definition/con-20032977">http://www.mayoclinic.org/diseases-conditions/depression/basics/definition/con-20032977</a>	n/a



DTX 881	Stahl, Stephen M. et al., SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants, CNS Spectrums (2005)	n/a
DTX 882	WebMD, Stopping Antidepressants: Is it Withdrawal? (2015) <a href="http://www.webmd.com/depression/guide/withdrawal-from-antidepressants">http://www.webmd.com/depression/guide/withdrawal-from-antidepressants</a>	n/a
DTX 883	Wolfe, Robert M., Antidepressant Withdrawal Reactions, American Family Physician (1997)	n/a
DTX 884	Cymbalta Label: 01-30-2009	CYM-02327672
DTX 885	Email from FDA to Lilly, 10-21-2004	CYM-01735330
DTX 886	Complaint, Hagain-Brown (ED Va.), (ECF 01), 11-26-2014	n/a
DTX 887	Cymbalta Clinical Study Results - Summaries Eli Lilly & Co. Clinical Trial Website <a href="http://lillytrials.com/results/Cymbalta.pdf">http://lillytrials.com/results/Cymbalta.pdf</a>	n/a
DTX 888	Email from Qi Zhang to D. Perahia, subject "Re: abrupt vs taper discontinuation," 10-02-2008	CYM-01795150
DTX 889	Attachment to 10-02-2008 Email from Qi Zhang to D. Perahia, subject "Re: abrupt vs taper discontinuation"	CYM-01795152
DTX 890	Multistudy-analyses Reports of Analyses of Data from More than One Study for Cymbalta (Duloxetine hydrochloride) Chronic Pain, 05-12-09	CYM-00193633
DTX 891	Supportive Optional Document to the Duloxetine Core Data Sheet Pre-Read Based on Clinical Trial Data in the Adult Population, 03-06-2012 [Designated as Wohlreich Ex. 15]	CYM-01868698
DTX 892	Clinical Trial Study: HMBU - Regulatory Response	CYM-00144439
DTX 893	Clinical Trial Study: HMCQ - Regulatory Response	CYM-00148929
DTX 894	Email from D. Perahia to J. Plewes, subject "Re: RESOLUTION of issue Re: Cymbalta: Slides and Study Citation for 30 mg "down-titration" dose, 04-16-2007	CYM-01937389
DTX 895	Email from M. Detke to M. Wohreich, subject "Re: Draft:: suggested wording for initial dosing change in LEAPS. Comments/suggestion welcomed.," 03-12-2004	CYM-02805689
DTX 896	Cymbalta Label: PV7219AMP, 09-07-2011 [Designated as Ahmed Ex. 03]	
DTX 897	Perahia, David G. et al., Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder, Journal of Affective Disorders (2005) [Designated as Ahmed Ex. 04]	
DTX 898	Cymbalta Label: PV7219AMP, 09-07-2011 [Designated as Bahadori Ex. 02]	CYM-00028678
DTX 899	Cymbalta Label 6-13-2007 [Designated as Detke Ex. 30]	CYM-01092811
DTX 900	Clinical Study Report: HMDU [Designated as Glenmullen Ex. 12]	CYM-00755360
DTX 901	Cymbalta Data Impact Test with PCPs Powerpoint [Designated as Morris Ex. 03]	CYM-02784272

DTX 902	FDA Submission (excerpt), 03-24-2003 [Designated as Morris Ex. 04]	CYM-00705893
DTX 903	Cymbalta Label: PV5906AMP, 11-28-2007 [Designated as Morris Ex. 05]	CYM-01097939
DTX 904	Clinical Study Report: 5.3.5.3. Multistudy-Analyses [Designated as Morris Ex. 06]	CYM-00193633
DTX 905	Paxil CR Label [Designated as Morris Ex. 07]	n/a
DTX 906	Paxil CR Label [Designated as Morris Ex. 08]	n/a
DTX 907	Schatzberg, Alan F. et al., Antidepressant Discontinuation Syndrome: An Update on Serotonin Reuptake Inhibitors, J. Clin. Psychiatry 1997) [Designated as Morris Ex. 09]	n/a
DTX 908	Declaration of Kathy A. Landen, Saavedra (ECF 126), 03-03-2014	n/a
DTX 909	Declaration of Sarah L. Helgeson, Saavedra (ECF 55), 03-27-2013	n/a
DTX 910	Declaration of Sarah L. Helgeson, Saavedra (ECF124), 03-03-2013	n/a
DTX 911	Declaration of Sharon Hoog, M.D., Saavedra (ECF 56) 03-27-2013	n/a
DTX 912	Defendant's Notice of Motion & Motion for Summary Judgment, Saavedra (ECF 54) 03-27-2013	n/a
DTX 913	Defendant's Motion for Summary Judgment, Carnes (ECF 24) 09-09-2013	n/a
DTX 914	Opinion and Order re Motion for Summary Judgment, Carnes (ECF 29) 12-16-2013	n/a
DTX 915	Opinion, McDowell (ECF 54) 02-26-2015	n/a
DTX 916	Letter to FDA from Lilly, 11-13-2009	CYM-00159733
DTX 917	Labeling Submission (excerpt), 11-19-2009	CYM-00159809
DTX 918	Labeling Submission (excerpt), 05-15-2009	CYM-00181988
DTX 919	Labeling Submission (excerpt), 11-12-2009	CYM-00300391
DTX 920	Labeling Submission (excerpt), 11-19-2009	CYM-00300421
DTX 921	Labeling Submission (excerpt), 04-29-2011	CYM-00319575
DTX 922	Labeling Submission (excerpt), 09-09-2011	CYM-00324272
DTX 923	Email from P. Hiren to M. Kuntz, subject "RE: NDA 21427/S034," 10-31-2011	CYM-00325070
DTX 924	Labeling Submission (excerpt), 09-16-2011	CYM-00331199
DTX 925	Email from M. Kuntz to H. Patel, subject "RE: NDA 21427_S-032_S-038_ ...," 04-27-2012	CYM-00382472
DTX 926	Email from H. Patel to M. Kuntz, subject "RE: NDA 21427_S-032_S-038_ ...," 06-04-2012	CYM-00382642
DTX 927	Labeling Submission (excerpt), 04-03-2012	CYM-00504811
DTX 928	Integrated Summary of Safety, 11-12-2001	CYM-00702033
DTX 929	Labeling Submission (excerpt), 12-22-2003	CYM-00708291
DTX 930	Letter to Lilly from FDA, 09-13-2002	CYM-00727673
DTX 931	Letter to Lilly from FDA (excerpt), 01-12-2005	CYM-00728864

DTX 932	Medication Guide: PV5280AMP	
DTX 933	Labeling Submission (excerpt), 12-13-2007	CYM-01093765
DTX 934	Letter to Lilly from FDA, 08-28-2007	CYM-01112659
DTX 935	Letter to Lilly from FDA (incl. attachment), 09-09-2005	CYM-01236531
DTX 936	Letter to Lilly from FDA (incl. attachment), 09-21-2007	CYM-01250524
DTX 937	Clinical Study Report: HMDT	CYM-01737172
DTX 938	CDER Approval Package, NDA 21-427/S-015, S-017 (excerpts)	
DTX 939	CDER Medical Review, NDA 21-733 (excerpts)	
DTX 940	CDER Medical Review, NDA 22-148 (excerpts)	
DTX 941	CDER Medical Review, NDA 22-516 (excerpts)	
DTX 942	Celexa Medication Guide 08/12/2011	
DTX 943	Cymbalta Label, 01-30-2009	
DTX 944	Cymbalta Label, 08-02-2007	
DTX 945	Effexor Label & Medication Guide, 08-24-2012	
DTX 946	Effexor Label, 05-02-2001	
DTX 947	Effexor Medication Guide, 12-12-2012	
DTX 948	Effexor XR Label, 10-22-2002	
DTX 949	ICH, Guideline for Industry: Structure & Content of Clinical Study Reports (1996)	
DTX 950	Letter to Forest Laboratories from FDA, 04-08-2004	
DTX 951	Letter to Forest Laboratories from FDA, 08-12-2011	
DTX 952	Letter to GlaxoSmithKline from FDA, 03-21-2011	
DTX 953	Letter to Lilly from FDA (incl. attachment), 11-07-2010	
DTX 954	Letter to Lilly from FDA (incl. attachment), 3-26-2009	
DTX 955	Letter to Lilly from FDA, 01-16-2014	
DTX 956	Letter to Pfizer Pharmaceuticals from FDA, 08-19-2004	
DTX 957	Letter to Wyeth-Ayerst from FDA, 01-31-2003	
DTX 958	Lexapro Label, 08-29-2002	
DTX 959	Lexapro Label, 05-12-2011	
DTX 960	Lexapro Label, 11-27-2002	
DTX 961	Lexapro Label, 12-18-2003	
DTX 962	Paxil Label, 01-12-2005	
DTX 963	Paxil Label, 04-13-2001	
DTX 964	Paxil Label, 12-14-2001	
DTX 965	Brief Chronology, Ali [Designated as Glenmullen Ex. 03]	n/a
DTX 966	Discovery, Ali, Pls. Responses to Def First Set Interrogatories, 02-11-2015 [Designated as Ali Ex. 03]	n/a
DTX 967	Police Report, Ali	n/a
DTX 968	Police Report, Ali [Designated as Glenmullen Ex. 14]	n/a
DTX 969	Symptoms List, Ali [Designated as Glenmullen Ex. 04]	n/a
DTX 970	Medical Records, Ali, Alexandria Healthcare Center	ALIJ_AHC_0001
DTX 971	Medical Records, Ali, Alexandria Healthcare Center [Designated as Glenmullen Ex. 11]	ALIJ_AHC_0001
DTX 972	Medical Records, Ali, Arthritis Clinic of Northern V	ALIJ_ACNV_0001

DTX 973	Medical Records, Ali, Bijan Youssefi, M.D	ALIJ_YOUSSEFIB_0001
DTX 974	Medical Records, Ali, Center for Women's Health	ALIJ_CWH_0001
DTX 975	Medical Records, Ali, CVS PHARMACY	ALIJ_CP_0001
DTX 976	Medical Records, Ali, CVS PHARMACY [Designated as Ali Ex. 01]	ALIJ_CP_0001
DTX 977	Medical Records, Ali, CVS PHARMACY [Designated as Ahmed Ex. 02]	ALIJ_CP_0001
DTX 978	Medical Records, Ali, Dr. Anvita Parhar	ALIJ_PARHARA_0001
DTX 979	Medical Records, Ali, Dr. Thonia Gab-Allah	ALIJ_GABALLAH T_0001
DTX 980	Medical Records, Ali, INOVA Fairfax Hospital	ALIJ_IFH_0001
DTX 981	Medical Records, Ali, John P. McConnell, MD	ALIJ_MCCONNEL LJ_0001
DTX 982	Medical Records, Ali, Matthew D. Williams, M.D.	ALIJ_WILLIAMS M_0001
DTX 983	Medical Records, Ali, Mega Life &Health Ins. Co	ALIJ_MLHIC_0001
DTX 984	Medical Records, Ali, Mohammad Hogue, M.D	ALIJ_HOGUEM_0001
DTX 985	Medical Records, Ali, Mussarat Tahira, M.D	ALIJ_TAHIRAM_0001
DTX 986	Medical Records, Ali, Nasreem Sheikh, M.D	ALIJ_SHEIKHN_0001
DTX 987	Medical Records, Ali, Nevera Ahmed,MD	ALIJ_AHMEDN_0001
DTX 988	Medical Records, Ali, Nevera Ahmed,MD [Designated as Ahmed Ex. 01]	ALIJ_AHMEDN_0001
DTX 989	Medical Records, Ali, Nevera Ahmed,MD [Designated as Ali Ex. 02]	ALIJ_AHMEDN_0001
DTX 990	Medical Records, Ali, Nevera Ahmed,MD [Designated as Glenmullen Ex. 10]	ALIJ_AHMEDN_0001
DTX 991	Medical Records, Ali, Patriot Sports Medicine	ALIJ_PSM_0001
DTX 992	Medical Records, Ali, RITE-AID Corporation	ALIJ_RAC_0001
DTX 993	Medical Records, Ali, Virginia Hospital Center	ALIJ_VH_0001
DTX 994	Medical Records, Ali, Walter Wang, M.D.	ALIJ_WANGW_0001

Dated June 17, 2015

Respectfully submitted,  
/s/ Jeffrey Todd Bozman  
Jeffrey Todd Bozman (VSB 83679)  
Michael X. Imbroscio (*pro hac vice*)  
Paul W. Schmidt (*pro hac vice*)  
Phyllis A. Jones (*pro hac vice*)  
Brian Stekloff (*pro hac vice*)  
Brett C. Reynolds (*pro hac vice*)  
COVINGTON & BURLING LLP  
One CityCenter  
850 Tenth Street, N.W.  
Washington, DC 20003  
Tel: (202) 662-5335  
Fax: (202) 778-5335  
jbozman@cov.com  
*Attorneys for Defendant Eli Lilly and Company*

**CERTIFICATE OF SERVICE**

I hereby certify that on the 18th day of June, 2015, I will electronically file the foregoing with the Clerk of Court using the CM/ECF system, which will then send a notification of such filing (NEF) to the following:

Peter A. Miller  
Brielle Marie Hunt  
Miller Legal LLC  
175 S. Pantops Drive, Third Floor  
Charlottesville, VA 22911  
Tel: (434) 529-6909  
Fax: (888) 830-1488  
Email: PMiller@MillerLegalLLC.com  
bhunt@millerlegalllc.com

R. Brent Wisner, Esq. (*pro hac vice*)  
BAUM, HEDLUND, ARISTEI & GOLDMAN, P.C.  
12100 Wilshire Blvd., Suite 950  
Los Angeles, CA 90025  
Tel: (310) 207-3233  
Fax: (310) 820-7444  
Email: rbwisner@baumhedlundlaw.com

*Counsel for Plaintiff*

/s/ Jeffrey T. Bozman  
Jeffrey Todd Bozman (VA 83679)  
Covington & Burling LLP  
One CityCenter  
850 Tenth Street, NW  
Washington, DC 20001  
Tel: (202) 662-5829  
Fax: (202) 778-5829  
jbozman@cov.com  
*Counsel for Eli Lilly and Company*